Targeted therapy principle of Indian Iressa 13621079267 Indian Iressa

() For many patients, high medical expenses and medications have caused financial pain to many families. Due to the pressure that the economy has put on patients and even their families, some people have even worked hard to cure diseases and incurred debts just to save people. Therefore, many patients are deterred by the disease. In other words, There is no legal basis for treating a disease.
/ ( () In fact, I don’t need to say more. Many people know that layered price increases are the main reason for high drug prices. As a result, many examination fees and drug prices are ridiculously expensive.
/ ( () From the following chain, you can see why drugs are so expensive and examinations cost so much.
/ ( () The manufacturer’s national general agent, provincial agent, centralized bidding and price fixing enter the hospital (dean, pharmacy department ) Final retail price
/ ( () Here is a simple example. There is a medicine in a hospital. The bid price is . The price is still higher. Where does the higher part come from? I can guarantee that there is absolutely no rebate for commonly used low-priced drugs like this! Without rebates, the price is also very high? The manufacturer said that the public relations fee is very high. If you don’t add it, How can it be included in the drug price?
/ ( () This is an unspoken rule that is very familiar in the medical industry. As the saying goes, the wool comes from the sheep. If you don’t cheat consumers and patients, who will you cheat?
/ ( () So here, let me briefly explain why the Indian version of Iressa is a good choice?
/ ( () According to statistics, Iressa is commercially profitable The rich confirmation is also the epitome of the rapid progress of molecular targeted drugs in cancer treatment. In 2018, Iressa’s sales in China were 100 million yuan, while its old rival Tarceva (another targeted drug for lung cancer treatment) Drugs, produced by Roche Pharmaceuticals), also received sales revenue of . However, original drug is a unique concept in China, which refers to drugs whose patents have expired but are produced by the original patent holder. A reporter from the "Daily Economic News" investigated and learned that the prices of these two drugs are very high in mainland China. Expensive.
/ (() New drug R&D and innovation takes at least years and costs more than 100 million U.S. dollars. This is a widely circulated view in the pharmaceutical industry on the time and financial resources required to develop new drugs. "Forbes" magazine in the review of large pharmaceutical companies After analyzing the number of drug approvals and R&D expenses during the same period from 2014 to 2017, we came to the conclusion that the research and development of new drugs requires at least 100 million U.S. dollars. Among them, AstraZeneca ranks first with an average R&D expense of 100 million U.S. dollars.
/ ( () Let’s take Nexavar as an example. Germany’s Bayer Nexavar’s patent is valid until 2020, but the Indian Patent Office issued a compulsory license to large Indian pharmaceutical companies as early as 2018, allowing them to legally copy Nexavar. Bayer filed an infringement lawsuit last year, but was still compulsorily licensed by the Indian authorities on the grounds that the German version was too expensive and ordinary people could not afford it.